Publisher
Springer Science and Business Media LLC
Reference70 articles.
1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer Statistics, 2017. CA Cancer J. Clin. 67, 7–30 (2017).
2. Achkar, T. & Tarhini, A. A. The use of immunotherapy in the treatment of melanoma. J Hematol. Oncol. 10, 88 (2017).
3. Kalal, B. S., Upadhya, D. & Pai, V. R. Chemotherapy Resistance Mechanisms in Advanced Skin Cancer. Oncol. Rev. 11, 326 (2017).
4. Omholt, K., Platz, A., Kanter, L., Ringborg, U. & Hansson, J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin. Cancer Res. 9, 6483–6488 (2003).
5. Liu, M. et al. Efficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trials. Oncotarget 8, 32258–32269 (2017).
Cited by
48 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献